Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Notes Payables (2023 - 2025)

Cresco Labs' Notes Payables history spans 3 years, with the latest figure at $10.8 million for Q4 2025.

  • For Q4 2025, Notes Payables fell 9.64% year-over-year to $10.8 million; the TTM value through Dec 2025 reached $10.8 million, down 9.64%, while the annual FY2025 figure was $10.8 million, 9.64% down from the prior year.
  • Notes Payables reached $10.8 million in Q4 2025 per CRLBF's latest filing, down from $11.9 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $11.9 million in Q4 2024 to a low of $10.8 million in Q4 2025.
  • Average Notes Payables over 3 years is $11.5 million, with a median of $11.8 million recorded in 2023.
  • Peak YoY movement for Notes Payables: grew 0.99% in 2024, then dropped 9.64% in 2025.
  • A 3-year view of Notes Payables shows it stood at $11.8 million in 2023, then grew by 0.99% to $11.9 million in 2024, then decreased by 9.64% to $10.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRLBF's Notes Payables are $10.8 million (Q4 2025), $11.9 million (Q4 2024), and $11.8 million (Q4 2023).